Compugen Ltd (CGEN.OQ)
3.85USD
25 Sep 2018
$-0.05 (-1.28%)
$3.90
$3.85
$3.90
$3.85
19,249
28,107
$5.00
$2.25
About
Overall
| Beta: | 0.65 |
| Market Cap(Mil.): | $175.64 |
| Shares Outstanding(Mil.): | 51.13 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CGEN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.68 | 32.76 |
| EPS (TTM): | -0.67 | -- | -- |
| ROI: | -52.36 | 1.79 | 14.61 |
| ROE: | -54.94 | 3.28 | 16.33 |
BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018
* COMPUGEN LTD - BAYER PLANS TO ADVANCE CANCER IMMUNOTHERAPY PROGRAM INTO FIRST-IN-HUMAN TRIALS IN 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Deals of the day-Mergers and acquisitions
April 2 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ** General Electric Co's healthcare unit said it would sell its information technology business to private equity firm Veritas Capital for $1.05 billion in cash as it sharpens its focus on smart diagnostics and connected devices. ** ReNew Power, backed by Goldman Sachs and Canada Pension Plan Investment Board (CPPIB), said it has acquired Ostro Energy Private Ltd, backed by London-bas
BRIEF-Compugen Announces Exclusive License Agreement With Medimmune
* CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES Source text (https://bit.ly/2GsywkV) Further company coverage: (Reuters.Brief@thomsonreuters.com)
Compugen, AstraZeneca unit in cancer drug development deal
JERUSALEM Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds).
Compugen, AstraZeneca unit in cancer drug development deal
JERUSALEM, April 2 Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million.
Competitors
| Price | Chg | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $43.79 | -0.14 |
| Roche Holding Ltd. (ROG.S) | CHF236.15 | -- |
| Roche Holding Ltd. (RO.S) | CHF237.00 | -- |
| Abbott Laboratories (ABT.N) | $72.20 | +0.76 |
| Bristol-Myers Squibb Co (BMY.N) | $61.82 | +0.23 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,034.45 | -- |
| Amgen, Inc. (AMGN.OQ) | $206.46 | -0.75 |
| Quest Diagnostics Inc (DGX.N) | $107.59 | 0.00 |
Estimates